LNTH Stock Analysis: Buy, Sell, or Hold?
LNTH - Lantheus Holdings, Inc
$66.92
0.24 (0.36%)
▲
BUY
HIGH Confidence
Last Updated: January 30, 2026
Earnings: Feb 25, 2026
25d
Get Alerted When LNTH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: LNTH shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: LNTH shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$59.51
Based on -1.7% avg growth
INTRINSIC VALUE TODAY
$36.95
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: LNTH is currently trading at $66.92, which is considered fair relative to its 30-day fair value range of $65.88 to $68.24. The stock's valuation (Forward PE: 12.0) is in line with its historical norms (11.7). At these levels, the market is pricing in 0.7% annual earnings growth.
Technical Outlook: Technically, LNTH is in a strong uptrend. Immediate support is located at $63.37, while resistance sits at $69.20.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (5th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $83.85 (+25.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, LNTH is in a strong uptrend. Immediate support is located at $63.37, while resistance sits at $69.20.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (5th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $83.85 (+25.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$65.88 -
$68.24
Company Quality Score
57/100
(HOLD)
Options IV Signal
5th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
80.4%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 5th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 25.7% below Wall St target ($83.85)
- BULLISH: Expecting earnings turnaround to 0.7% growth with 1.4% revenue growth
Fair Price Analysis
30-Day Fair Range
$65.88 -
$68.24
Current vs Fair Value
FAIR
Expected Move (7 Days)
±$4.77
(7.1%)
Support & Resistance Levels
Support Level
$63.37
Resistance Level
$69.20
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
11.98
Wall Street Target
$83.85
(+25.7%)
Revenue Growth (YoY)
1.4%
Earnings Growth (YoY)
-77.1%
Profit Margin
11.0%
Valuation Premium vs History
+0.7% premium
PE vs Historical
12.0 vs 11.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.7%
(market-implied from PE analysis)
1-Year Target
$67.15
(+1%)
2-Year Target
$67.62
(+1%)
3-Year Target
$68.09
(+2%)
3-Yr Target (if PE normalizes)
(PE: 12→12)
PE COMPRESSION
$66.49
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: -7.4%)
$123.83
(+86%)
Base:
(SPY PE: 12.0, Growth: -7.4%)
$66.53
(0%)
Bear:
(PE: 10.2, Growth: -7.4%)
$56.55
(-15%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (28x PE), but valuation improves significantly next year (12x PE) as earnings recover.
Trailing PE: 28.17 | Current EPS (TTM): $2.41
Bull Case
$149.35
(+124%)
Analyst growth 100.0%, PE expands to 31.0
Base Case
$135.77
(+104%)
Market implied 100.0%, PE stable at 28.2
Bear Case
$46.16
(-31%)
Severe decline -20.0%, PE contracts to 23.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Last updated: January 30, 2026 5:54 PM ET
Data refreshes hourly during market hours. Next update: 6:54 PM
Data refreshes hourly during market hours. Next update: 6:54 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LNTH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Farallon Partners L L C/…
SELL
3365000 shares
2025-08-20
Rajiv A Patel
SELL
3365000 shares
2025-08-20
Farallon Partners L L C/…
SELL
41000 shares
2025-08-19
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$179 | 62 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$158 | 56 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 55 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 57 HOLD |
|
TEVA
Teva Pharma Industries L… |
STRONG BUY
11 analysts |
$35 | 54 HOLD |
Advanced LNTH Option Strategies
Professional options setups generated by AI based on today's LNTH price and gamma walls.
